Rajneesh Nath

机构：Rutgers, The State University of New Jersey, The University of Texas MD Anderson Cancer Center, Banner MD Anderson Cancer Center

发表论文 161 篇 · 总被引 2619 次 · h-index 26

代表论文

Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies (2025 · Journal of Clinical Oncology · 被引 39)
Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study (2024 · Blood · 被引 22)
Randomized Phase III SIERRA Trial of 131 I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML (2024 · Journal of Clinical Oncology · 被引 16)
Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study (2025 · Blood Advances · 被引 15)
Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Updated Follow-up of Transcend CLL 004 (2024 · Blood · 被引 10)
Safety and Efficacy Results from a Randomized, Double-Blind, Placebo-Controlled Cohort 2 of a Phase 1b Study of an Investigational Live Biotherapeutic, SER-155, in Adults Undergoing Allo-HCT (2025 · Transplantation and Cellular Therapy · 被引 5)